Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Tradenride who wrote (63)	6/4/2005 11:51:49 AM
From: wwtmm1	Respond to of 237

Same post over and over.......now quickly go to I-Hub, don't pass go, and make the same post.

To: Tradenride who wrote (63)	6/5/2005 11:03:19 PM
From: T's&G's	Read Replies (1) \| Respond to of 237

Trade-- Cataldo actually saved HIV.. FWIW, HIV is on the AMEX and though on life support, pps-wise, is none the less alive. IMO HIV's problem is its limited-use product, not Cataldo. It's a miracle HIV's pps is what it is. MCET, OTOH, has a respectable patent stable and the thumbs up from BMS, Pfizer, and Japanese Eisai Pharmaceuticals. MCET has one product currently on the market plus a chock-full pipeline of liver -related products to be, not to mention SYBIOL, the "artificial" liver machine which is showing signs of renewed activity.